8-K: Alumis and ACELYRIN Update Merger Plans, Highlight Pipeline Milestones

Alumis Inc. and ACELYRIN, INC. have released an updated presentation regarding their proposed merger, initially announced on February 6, 2025, focusing on upcoming milestones and the potential of their combined pipeline.

Summary

• Alumis and ACELYRIN have updated their presentation regarding their proposed merger.
• The merger aims to create a late-stage clinical biopharma company focused on immune-mediated diseases.
• The combined company will have a differentiated pipeline with multiple upcoming milestones.
• Topline data from the Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis is now expected in Q1 2026.
• Topline data from the Phase 2b LUMUS trial in systemic lupus erythematosus is on track for readout in 2026.
• A Phase 2 clinical trial for Alumis' A-005 in multiple sclerosis is expected to initiate in 2025, with topline data in 2026.
• The merger includes the addition of lonigutamab, an anti-IGF-1R for thyroid eye disease (TED), with committed capital for clinical development.
• The pro forma cash balance is approximately $737 million as of December 31, 2024, providing a cash runway into 2027.
• The combined company is expected to benefit from a world-class leadership team.
• The ACELYRIN Board determined that a transaction that supported the continued development of lonigutamab represented the best opportunity for long-term value creation for ACELYRIN stockholders.
• The combination with Alumis is estimated to be ~41%-48% value accretive to ACELYRIN Stockholders.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the merger, highlighting potential value creation and pipeline milestones. However, it also acknowledges risks and uncertainties associated with the transaction, leading to a moderately positive sentiment.

Positives

• The merger creates a late-stage clinical biopharma company with a focus on immune-mediated diseases.
• The combined company has a differentiated pipeline with multiple upcoming milestones.
• The pro forma cash balance of ~$737 million provides a cash runway into 2027.
• The leadership team has a proven record of operating discipline and capital efficiency.
• The merger is expected to be value accretive to ACELYRIN stockholders.
• The transaction is the best path forward to exploit the full potential opportunity for Lonigutamab.

Negatives

• The Phase 3 topline data for ESK-001 in psoriasis is now expected in Q1 2026, which is a delay from the previously announced 2H 2026.
• The merger is subject to various risks and uncertainties, including regulatory and stockholder approvals.
• The integration of the two companies may not occur as anticipated, and the combined company may not achieve the expected growth prospects.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required approvals may not be received, or other conditions to the transaction may not be satisfied.
• The announcement or completion of the transaction may negatively impact the companies' ability to attract and retain key personnel.
• The transaction may divert management's attention from ongoing business operations.
• Legal proceedings related to the transaction could result in expense or delay.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• Integration of the two companies post-closing may not occur as anticipated.
• Potential delays in initiating, enrolling or completing preclinical studies and clinical trials.

Future Outlook

The combined company aims to innovate, develop, and commercialize transformative therapies for immune-mediated diseases, with multiple clinical readouts expected in the near term and a cash runway into 2027.

Management Comments

• The ACELYRIN Board determined that a transaction that supported the continued development of lonigutamab represented the best opportunity for long-term value creation for ACELYRIN stockholders.

Industry Context

The merger reflects a trend in the biopharmaceutical industry towards consolidation to create larger entities with diversified pipelines and greater financial resources to develop and commercialize innovative therapies in the competitive immunology market.

Comparison to Industry Standards

• The combined company's focus on immune-mediated diseases aligns with the strategies of major players like Amgen, which has a significant presence in the immunology space with products like TEPEZZA (mentioned in the document).
• The development of TYK2 inhibitors like ESK-001 and A-005 positions the company to compete with other companies developing similar therapies for psoriasis, SLE, and MS, such as Bristol Myers Squibb (Deucravacitinib).
• The pursuit of a subcutaneous anti-IGF-1R therapy for TED (lonigutamab) aims to improve upon existing treatments like Tepezza, which is administered intravenously.

Stakeholder Impact

• Shareholders of both Alumis and ACELYRIN are expected to benefit from the potential value creation and synergies of the merger.
• Employees of both companies may experience changes as a result of the integration.
• Patients may benefit from the development of new therapies for immune-mediated diseases.

Next Steps

• Alumis intends to file a registration statement with the SEC, including a joint proxy statement/prospectus.
• Stockholder approvals from both Alumis and ACELYRIN will be required.
• The companies will continue to develop their clinical pipelines, with key data readouts expected in 2026.
• The clinical development plan for lonigutamab in TED will be finalized in mid-2025.

Key Dates